Swiss drugmakers face US pricing trade pressure
Share
- Switzerland's pharmaceutical sector is facing the prospect of a US trade investigation, with Interpharma — the Swiss pharmaceutical industry body — warning on 26 June that the country could be targeted over its drug pricing and reimbursement practices.
- The warning follows the US launching a formal Section 301 investigation into Germany just eight days earlier, accusing Berlin of systematically underpaying for innovative pharmaceutical products in ways that harm American commerce.
- Section 301 is a trade mechanism that allows the US administration to investigate foreign practices it deems unfair and, where findings warrant, impose tariffs on imports from the country under scrutiny.
Public hearings on the German investigation are scheduled for 22 September 2026, with Switzerland appearing to be next in line for similar scrutiny.
"Switzerland is a potential target,"
Interpharma chief executive René Buholzer said, pointing to ongoing revisions in Swiss health insurance ordinances as a contributing factor to Washington's concerns.
Pharmaceutical exports represent Switzerland's largest export category, with approximately US$35.5 billion in annual pharma shipments destined for the American market — the bulk of which is attributable to Basel-headquartered giants Roche and Novartis.
The US has previously threatened average tariffs of 39% on Swiss goods, though pharmaceutical products have been separately capped at 15% under prior agreements, which would still represent a substantial financial burden on US$35.5 billion in exports.
Washington's broader trade strategy centres on the argument that American patients pay disproportionately more for prescription drugs than those in other developed nations, effectively subsidising lower drug prices abroad.
Switzerland's position is complicated by its own domestic healthcare cost reforms, which were designed to adjust drug pricing and reimbursement ordinances with Swiss patients and budgets in mind, not to satisfy US trade negotiators.
Both Roche and Novartis have historically responded to American trade pressure by pledging increased investment and manufacturing on US soil, a playbook analysts expect both companies to deploy again if a formal investigation is initiated.
Investors with exposure to Roche or Novartis are being advised to monitor two key developments: whether the US formally opens a Section 301 investigation into Switzerland, and how the September hearings on Germany's case shape Washington's broader approach to pharmaceutical trade disputes.